# Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

> **NCT00032019** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 78 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00032019
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2004-12
- **Final completion:** 2009-04
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2016-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00032019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00032019, "Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00032019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*